Avalon/GSK Incubation Project Launches First Company, Focused On Celiac Disease
This article was originally published in The Pink Sheet Daily
New company Sitari will try to develop first drug therapy for celiac disease. Portfolio companies launched by GSK and Avalon also will have their own, dedicated CRO-like organization to handle much of their work.
You may also be interested in...
Celiac disease specialist Sitari was the first company formed under the six-year collaboration. Three were shut down and Avalon controls the other four, which aren't compatible with GSK's new R&D focus.
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.